IL18 and Alzheimer disease: Thus, palonosetron and/or MLA via the inhibition of caspase-11 and -1, as well as IL-1β and IL-18 intervene with the non-stop series of cytokine/NLRP3 inflammasome/microglial activation to reduce AD neuroinflammation.